Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

Part of paid clinical trials in Seattle, Washington.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT04254133
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
MALE
Age
35 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • Questionnaire — BEHAVIORAL
    Complete questionnaire
  • Biospecimen Collection — PROCEDURE
    Provide saliva samples
  • Genetic Testing — DIAGNOSTIC_TEST
    Undergo genetic testing
  • Genetic Counseling — OTHER
    Undergo counseling
  • Laboratory Biomarker Analysis — OTHER
    Correlative Studies

Study Details

This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.

Key Dates

Start date
Nov 30, 2018
Status verified
Jan 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
1,360 participants (estimated)

Arms

  • Arm: Case Ascertainment
    Men with prostate cancer
  • Arm: Family Recruitment
    Male relatives of men with prostate cancer

Primary Outcome Measure

Identification of a population-based cohort of men with prostate cancer (PC) and germline deoxyribonucleic acid (DNA) repair gene (gDRG) mutations [ Time Frame: From the start of study through death (up to 20 years) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109-

Find similar trials in Seattle, WA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies